Posted: August 14, 2019 Shirish Gadgeel, MBBS, is the Mary Lou Kennedy Research Professor in Thoracic Oncology and a professor in the Division of Hematology/Oncology at the University of Michigan Rogel Cancer Center. He is the co-leader of the Thoracic Oncology Research Program and associate director for cancer care at Networking and Affiliated Centers. In an…

Posted: August 14, 2019 Mark A. Socinski, MD, executive medical director of AdventHealth Cancer Institute, spoke with the IASLC Lung Cancer News about his personal recommendations for TKI-refractory disease, especially for patients with EGFR mutations. He discussed the latest IMpower150 data,1 as well as the U.S. Food and Drug Administration’s (FDA’s) decision not to approve this…

Posted: August 14, 2019 Lorlatinib, a smallmolecule inhibitor of ALK and ROS1, was granted accelerated U.S. Food and Drug Administration approval in November 2018 for patients with ALK-positive metastatic NSCLC whose disease has progressed on crizotinib and at least one other ALK inhibitor or whose disease has progressed on alectinib or ceritinib as the first ALK…

By Christian Rolfo, MD, PhD, MBA, Dr.h.c., and Lori Alexander, MTPW, ELS, MWC Posted: August 14, 2019 Targeted therapy has become the standard of care in patients with advanced NSCLC and oncogenic drivers, and tissue biopsy has emerged as the gold standard in the molecular diagnosis of the disease. Guidelines recommend that all patients with newly…

By Emily F. Collier, MD; Roy S. Herbst, MD, PhD; and Sarah B. Goldberg, MD, MPH Posted: August 14, 2019 Dr. Emily F. Collier Dr. Roy S. Herbst Dr. Sarah B. Goldberg KEYNOTE-010 is an open-label phase II/ III study that compared pembrolizumab (2 mg/kg or 10 mg/kg every 3 weeks) with docetaxel in previously treated…